Lecture 3: Approaches to control allergenicity through animal biotechnology



Shigeru KAKUTA, PhD, DVM.



🔳 Mer

Q Search

Associate Professor

Department of Veterinary Medical Science / Research Center for Food Safety Graduate School of Agricultural and Life Sciences, The University of Tokyo



cial website of the United States government <u>Here's how you know ~</u>

← Home / News & Events / EDA Newsroom / Press Announcements / EDA Approves First-of-its-Kind Intentional Genomic Alteration in Line of Domestic Pigs for Both Human Food, Potential Therapeutic Uses

FDA NEWS RELEASE

FDA Approves First-of-its-Kind Intentional Genomic Alteration in Line of Domestic Pigs for Both Human Food, Potential Therapeutic Uses

Alteration intended to eliminate alpha-gal sugar on surface of pigs' cells

The New York Times

In a First, Man Receives a Heart From a Genetically Altered Pig

The breakthrough may lead one day to new supplies of animal organs for transplant into human patients.

Jan. 10, 2022

A 57-year-old man with life-threatening heart disease has received a heart from a genetically modified pig, a groundbreaking procedure that offers hope to hundreds of thousands of patients with failing organs.

It is the first successful transplant of a pig's heart into a human being. The eight-hour operation took place in Baltimore on Friday, and the patient, David Bennett Sr. of Maryland, was doing well on Monday, according to surgeons at the University of Maryland Medical Center.

"It creates the pulse, it creates the pressure, it is his heart," said Dr. Bartley Griffith, the director of the cardiac transplant program at the medical center, who performed the operation.

"It's working and it looks normal. We are thrilled, but we don't know what tomorrow will bring us. This has never been done before."



Dr. Bartley Griffith, left, performed the operation on David Bennett Sr. to receive a new heart from a genetically modified pig. University of Maryland School of Medicine

Genetically Modified Pig's Heart Is Transplanted Into a Second Patient

The first patient to receive such an organ died after two months. "At least now I have hope," the second recipient said before the surgery.

Sept. 22, 2023

Surgeons in Baltimore have transplanted the heart of a genetically altered pig into a man with terminal heart disease who had no other hope for treatment, the University of Maryland Medical Center announced on Friday.

It is the <u>second such procedure performed by the surgeons</u>. The first patient, David Bennett, 57, died two months after his transplant, but the pig heart functioned well and there were no signs of acute organ rejection, a major risk in such procedures.

The second patient, Lawrence Faucette, 58, a Navy veteran and married father of two in Frederick, Md., underwent the transplant surgery on Wednesday and is "recovering well and communicating with his loved ones," the medical center said in a statement.

Mr. Faucette, who had terminal heart disease and other complicated medical conditions, was so sick that he had been rejected from all transplant programs that use human donor organs.



Surgeons examine a pig heart during Lawrence Faucette's transplant surgery. Mark Teske/University of Maryland School of Medicine, via Associated Press



Mr. Faucette, a 20-year Navy veteran with heart failure from Frederick, Md., and his wife, Ann Faucette, before the surgery. Mr. Faucette, 58, received a genetically altered pig heart at the University of Maryland Medical Center. University of Maryland Medical Center

Table S1: Genetic Modifications of Source Animal for Cardiac Xenotransplantation				
Genetic Modification	Mechanisms	Properties		
	Xenogeneic Carbohydrate Knockout			
Galactose-α-1,3-galactose KO (GTKO)	Deletion of immunogenic Galactose-α-1,3-galactose (Gal) glycan through knockout of the synthetic enzyme alpha1,3-galactosyltransferase (GT)			
β1,4-N- acetylgalactosyltransferase KO (B4GalKO)	Deletion of immunogenic blood group SDa antigen through knockout of the synthetic enzyme (B4GalNT2)	Anti- Immunogenic		
CMP-N-acetyIneuraminic acid hydroxylase KO (CMAHKO)	Deletion of immunogenic glycan N- glycolylneuraminic acid (Neu5Gc) through knockout of the synthetic enzyme CMP-N-acetylneuraminic acid hydroxylase (CMAH)			
Growth Hormone Receptor Knockout (GHRKO)	Reduction of downstream insulin growth factor-1 (IGF-1) signaling	Reduce intrinsic graft growth		
	Human Transgene Expression			
CD46	Suppress human complement activity by mediating cleavage of C3b and C4b complement deposition	Complement Regulation		
Decay Accelerating Factor (DAF)	Inhibits C3 and C5 convertase enzymes and downstream complement activation			
Endothelial Cell Protein C Receptor (EPCR)	Activates Protein C	Anti-Coagulation		
Thrombomodulin (TBM)	Binds human thrombin, and activates Protein C via activated thrombin			
Hemeoxygenase-1 (HO-1)	Decreases oxidative products	Anti-		
CD47	Interacts with macrophage signal regulatory protein (SIRP)α to prevent opsonization and phagocytosis of xenogeneic tissue	Inflammatory		

GGTA1 gene

N Engl J Med 387:35-44 (2022)

Galactose-a-1,3-galactose (a-Gal) is

present in organs and muscles from most mammals (but not humans, apes, and old world monkeys) as a glycan conjugated to both proteins and lipids.

biosynthesized by α 1,3-galactosyltransferase encoded in *GGTA1* gene, which has inactive mutation in humans, apes, and old world monkeys.

recognized as target epitopes of immunoglobulin (Ig)E, that commonly contributed to clinical symptoms in α -Gal syndrome.





Nat Biotechnol 39: 393-400 (2021)

GalSafe pigs

could now provide a source of meat for people who develop tick bite-induced allergic reactions to the sugar, a condition known as α -Gal syndrome, including red meat allergy.



Gene-edited pigs could solve the human organ transplant shortage. Credit: Pulsar Imagens / Alamy Stock Photo



1st generation of GGTA1 gene deficient pigs

Production of α-1,3-Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning

Liangxue Lai,¹ Donna Kolber-Simonds,³ Kwang-Wook Park,¹ Hee-Tae Cheong,^{1,4} Julia L. Greenstein,³ Gi-Sun Im,^{1,5} Melissa Samuel,¹ Aaron Bonk,¹ August Rieke,¹ Billy N. Day,¹ Clifton N. Murphy,¹ David B. Carter,^{1,2} Robert J. Hawley,³ Randall S. Prather^{1*}

The presence of galactose α -1,3-galactose residues on the surface of pig cells is a major obstacle to successful xenotransplantation. Here, we report the production of four live pigs in which one allele of the α -1,3-galactosyltransferase locus has been knocked out. These pigs were produced by nuclear transfer technology; clonal fetal fibroblast cell lines were used as nuclear donors for embryos reconstructed with enucleated pig oocytes.



Table 1. Pregnancies carried to term after transfer of embryos reconstructed with GGTA1 knockout cell lines.

Surrogate (estrus day)	Donor line	NT embryos	Outcome
O212 (0)	F7-H6	116	Mated surrogate Seven born 9/21/01 One NT derived formale night
O226 (1) O230 (1)	F3-C5 F7-H6 cultured	92 130	Four NT-derived female piglets born 10/19/01 Two NT-derived female piglets born 10/15/01

Science 295:1089-92 (2002)

Targeted disruption of the α 1,3-galactosyltransferase gene in cloned pigs

Yifan Dai¹⁺, Todd D. Vaught¹, Jeremy Boone¹, Shu-Hung Chen¹, Carol J. Phelps¹, Suyapa Ball¹, Jeff A. Monahan¹, Peter M. Jobst¹, Kenneth J. McCreath², Ashley E. Lamborn¹, Jarnie L. Cowell-Lucero¹, Kevin D. Wells¹, Alan Colman², Irina A. Polejaeva¹, and David L. Ayares¹

Galactose- α 1,3-galactose (α 1,3Gal) is the major xenoantigen causing hyperacute rejection in pig-to-human xenotransplantation. Disruption of the gene encoding pig α 1,3-galactosyltransferase (α 1,3GT) by homologous recombination is a means to completely remove the α 1,3Gd al pitopes from xenografts. Here we report the disruption of one allele of the pig α 1,3GT gene in both male and female porcine primary fetal fibroblasts. Targeting was confirmed in 17 colonies by Southern blot analysis, and 7 of them were used for nuclear three disruption colony, we produced six cloned temale pigtes of which five were of normal weight and apparently healthy. Southern blot analysis confirmed that these five pigtes contain one disrupted pig α 1,3GT allele.



Figure 3. Five α 1,3GT gene knockout piglets at 2 weeks of age.

Nat Biotechnol 20:251-55 (2002)

For Food Safety,

- 1, transgene insertion, including drug selection marker gene, vector sequence, etc.
- 2, unexpected (off-target) mutation
- in genetically modified animals are not appropriate.



Transgenic pig carrying green fluorescent protein (GFP) derived from jellyfish **PNAS** 110(16):6334-39 (2013)

How generate target gene-modified animals "without" exogenous gene integration?

Genetic scissors: a tool for rewriting the code of life

The Nobel Prize in Chemistry 2020

The Nobel Prize in Chemistry 2020

Emmanuelle Charpentier Jennifer A. Doudna

Share this





© Nobel Media. III. Niklas Elmehed. Emmanuelle Charpentier Prize share: 1/2



Prize share: 1/2

"for the development of a method for genome editing"

Genome editing platforms and mechanisms for DSB repair with endogenous DNA.



Major methods for generating genetically modified pigs using gene editors Cytoplasmic microinjection (CMI) Genomic DNA Somatic cell nuclear transfer (SCNT) Introduction of gene editors Gene editing Gene-edited cells R into cytoplasm 200 Enucleation Genomic DNA **Electroporation (EP)** Genomic DNA Nuclear transfer Somatic cells 20 A bo Gene editing Introduction of gene editors via Gene editing electroporation J Reprod Dev 67: 177-187 (2021)

BMC Biotechnology

RESEARCH ARTICLE



Xenotransplantation WILEY

Efficient generation of *GGTA1*-deficient pigs by electroporation of the CRISPR/Cas9 system into in vitro-fertilized zygotes

Fuminori Tanihara¹, Maki Hirata^{1*}⁽⁶⁾, Nhien Thi Nguyen¹, Osamu Sawamoto², Takeshi Kikuchi², Masako Doi² and Takeshige Otoi¹



ORIGINAL ARTICLE

(A)

Generation of cattle knockout for galactose- α 1,3-galactose and N-glycolylneuraminic acid antigens

Andrea Perota¹ | Irina Lagutina¹ | Roberto Duchi¹ | Elisa Zanfrini¹ | Giovanna Lazzari^{1,2} | Jean Paul Judor^{3,4} | Sophie Conchon^{3,4} | Jean Marie Bach⁵ | Tomaso Bottio⁶ | Gino Gerosa⁶ | Cristina Costa⁷ | Manuel Galiñanes⁸ | Jean Christian Roussel⁹ | Vered Padler-Karavani¹⁰ | Emanuele Cozzi¹¹ | Jean Paul Soulillou^{3,4} | Cesare Galli^{1,2}

Cremona, Italy.



Cas9-expressing chickens and pigs as resources for genome editing in livestock

Beate Rieblinger^{a,1}, Hicham Sid^{b,1}, Denise Duda^{b,1}, Tarik Bozoglu^{c,d,1}, Romina Klinger^b, Antonina Schlickenrieder^b, Kamila Lengyel^b, Krzysztof Flisikowski^a, Tatiana Flisikowska^a, Nina Simm^a, Alessandro Grodziecki^a, Carolin Perleberg^a, Andrea Bähr^{c,d}, Lucie Carrier^{e,f}, Mayuko Kurome^{g,h}, Valeri Zakhartchenko^{g,h}, Barbara Kessler^{g,h}, Eckhard Wolf^{g,h}, Lutz Kettlerⁱ, Harald Lukschⁱ, Ibrahim T. Hagag^j, Daniel Wise^k, Jim Kaufman^{k,I}, Benedikt B. Kaufer^{j,2}, Christian Kupatt^{c,d,2}, Angelika Schnieke^{a,2}, and Benjamin Schusser^{b,2}

Technical University Munich



In vivo genome editing in SpCas9 transgenic pigs and chickens can be easily performed by transducing with an AAV virus encoding gRNAs



Ex vivo primordial germ cell (PGC)-mediated method for genome editing in the chicken



- 1, Chicken PGCs are isolated from embryonic blood or gonad
- 2, Ex vivo genome editing in cultured PGCs
- 3, Selection of genome-edited PGCs
- 4, Injection into the dorsal aorta of recipient chicken embryos
- 5, Generation of potential germ-line chimeric chicken
- 6, Chimeras are mated with wild-type partners to produce heterozygous mutant (+/-) chickens

HIROSHIMA UNIVERSITY

Confirming the safety of genetically edited allergen-free eggs

Researchers have created a genetically edited allergen-free chicken egg that may be safe for those with egg white allergies.



Scientists from Hiroshima University produced OVM knocked out chickens using genome editing tools. Colored chickens are knockout chickens. (Ezaki et al. 2023, Food and Chemical Toxicology)



Summary

Current genetic engineering techniques enable to produce genetically modified livestock including pigs, cattle and chickens.

GGTA1 deficient pigs, which lack galactose- α -1,3-galactose (α -Gal) sugar molecule, for potentially allergy-free meat were established.

FDA approved *GGTA1* deficient pigs (facility in northern lowa) for human food in 2021, but not yet commercially available.

Exogenous gene integration-free *GGTA1* deficient cattle, *OVM* deficient chickens were also generated.

These genetically modified animals are thought as new livestock for potentially allergy-free food, but it is still in the research stage.